Overview

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

Status:
RECRUITING

Trial end date:
2028-02-29

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital of Xiamen University

Treatments:

Injections
Thymalfasin